Roth Capital Begins Coverage on Galmed Pharmaceuticals Ltd. (GLMD)

Roth Capital began coverage on shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in a research note published on Wednesday morning, reports. The firm issued a buy rating and a $32.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. HC Wainwright boosted their price objective on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a buy rating in a research report on Tuesday, August 8th. Seaport Global Securities restated a buy rating and issued a $19.00 price objective on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. Maxim Group restated a buy rating and issued a $14.00 price objective (up from $9.00) on shares of Galmed Pharmaceuticals in a research report on Monday, July 31st. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.00 price objective for the company in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Galmed Pharmaceuticals currently has an average rating of Buy and an average price target of $18.30.

Galmed Pharmaceuticals (NASDAQ GLMD) traded up $0.16 during trading on Wednesday, hitting $7.81. The stock had a trading volume of 45,560 shares, compared to its average volume of 35,428. Galmed Pharmaceuticals has a 1-year low of $3.04 and a 1-year high of $9.59.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. KCG Holdings Inc. purchased a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.25% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply